n

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

References:

1. Barratt J, Suzuki Y, et al. Safety, tolerability, and efficacy of mezagitamab (TAK-079) as add-on to standard-of-care therapy in individuals with primary IgA nephropathy: week 96 data from an open-label phase 1b study. Poster FR-PO0808 presented at: American Society of Nephrology (ASN) Kidney Week Annual Meeting; November 5-9, 2025; Houston, Texas, USA.
2. Cheung CK, Alexander S, et al. The pathogenesis of IgA nephropathy and implications for treatment. Nature Reviews Nephrology; 2024:1‐15.
3. IgA nephropathy. National Institutes of Health.https://www.niddk.ni
=*=*=*=*=*=
当前为第14/15页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页